159 related articles for article (PubMed ID: 37276599)
1. Genotype-guided drug prescribing vs. usual care reduced clinically relevant adverse drug reactions at 12 wk.
Holbrook AM
Ann Intern Med; 2023 Jun; 176(6):JC70. PubMed ID: 37276599
[TBL] [Abstract][Full Text] [Related]
2. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Swen JJ; van der Wouden CH; Manson LE; Abdullah-Koolmees H; Blagec K; Blagus T; Böhringer S; Cambon-Thomsen A; Cecchin E; Cheung KC; Deneer VH; Dupui M; Ingelman-Sundberg M; Jonsson S; Joefield-Roka C; Just KS; Karlsson MO; Konta L; Koopmann R; Kriek M; Lehr T; Mitropoulou C; Rial-Sebbag E; Rollinson V; Roncato R; Samwald M; Schaeffeler E; Skokou M; Schwab M; Steinberger D; Stingl JC; Tremmel R; Turner RM; van Rhenen MH; Dávila Fajardo CL; Dolžan V; Patrinos GP; Pirmohamed M; Sunder-Plassmann G; Toffoli G; Guchelaar HJ;
Lancet; 2023 Feb; 401(10374):347-356. PubMed ID: 36739136
[TBL] [Abstract][Full Text] [Related]
3. Use of a multi-gene pharmacogenetic panel reduces adverse drug effects.
Cavallari LH; Johnson JA
Cell Rep Med; 2023 May; 4(5):101021. PubMed ID: 37084734
[TBL] [Abstract][Full Text] [Related]
4. Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials.
Goulding R; Dawes D; Price M; Wilkie S; Dawes M
Br J Clin Pharmacol; 2015 Oct; 80(4):868-77. PubMed ID: 25060532
[TBL] [Abstract][Full Text] [Related]
5. The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.
Cavallari LH; Beitelshees AL; Blake KV; Dressler LG; Duarte JD; Elsey A; Eichmeyer JN; Empey PE; Franciosi JP; Hicks JK; Holmes AM; Jeng L; Lee CR; Lima JJ; Limdi NA; Modlin J; Obeng AO; Petry N; Pratt VM; Skaar TC; Tuteja S; Voora D; Wagner M; Weitzel KW; Wilke RA; Peterson JF; Johnson JA
Clin Transl Sci; 2017 May; 10(3):143-146. PubMed ID: 28294551
[No Abstract] [Full Text] [Related]
6. Genetic literacy series: clinical application of pharmacogenetics for adverse reactions to antiepileptic drugs.
Zhang Z; Wu Y; Tan NC; Jiang Y
Epileptic Disord; 2019 Aug; 21(4):330-336. PubMed ID: 31403464
[TBL] [Abstract][Full Text] [Related]
7. Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing.
Lee YM; Danahey K; Knoebel RW; Ratain MJ; Meltzer DO; O'Donnell PH
Pharmacogenet Genomics; 2019 Feb; 29(2):23-30. PubMed ID: 30531378
[TBL] [Abstract][Full Text] [Related]
8. Using pharmacogenetics to prevent severe adverse reactions to capecitabine.
García-González X; López-Fernández LA
Pharmacogenomics; 2017 Aug; 18(13):1199-1213. PubMed ID: 28746000
[No Abstract] [Full Text] [Related]
9. A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.
Plumpton CO; Roberts D; Pirmohamed M; Hughes DA
Pharmacoeconomics; 2016 Aug; 34(8):771-93. PubMed ID: 26984520
[TBL] [Abstract][Full Text] [Related]
10. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
Dunnenberger HM; Crews KR; Hoffman JM; Caudle KE; Broeckel U; Howard SC; Hunkler RJ; Klein TE; Evans WE; Relling MV
Annu Rev Pharmacol Toxicol; 2015; 55():89-106. PubMed ID: 25292429
[TBL] [Abstract][Full Text] [Related]
11. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping.
Schildcrout JS; Denny JC; Bowton E; Gregg W; Pulley JM; Basford MA; Cowan JD; Xu H; Ramirez AH; Crawford DC; Ritchie MD; Peterson JF; Masys DR; Wilke RA; Roden DM
Clin Pharmacol Ther; 2012 Aug; 92(2):235-42. PubMed ID: 22739144
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx).
Picard N; Boyer JC; Etienne-Grimaldi MC; Barin-Le Guellec C; Thomas F; Loriot MA;
Therapie; 2017 Apr; 72(2):185-192. PubMed ID: 28237406
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.
Shah RR
Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578
[TBL] [Abstract][Full Text] [Related]
14. Are we PREPAREd? Concerning the "PREemptive Pharmacogenomics Testing for Preventing Adverse Drug Reactions (PREPARE) Study".
De Carmo Campos A; Cardoso ML; Vicente A
Acta Med Port; 2023 Oct; 36(10):689-690. PubMed ID: 37788651
[No Abstract] [Full Text] [Related]
15. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.
Phillips EJ; Sukasem C; Whirl-Carrillo M; Müller DJ; Dunnenberger HM; Chantratita W; Goldspiel B; Chen YT; Carleton BC; George AL; Mushiroda T; Klein T; Gammal RS; Pirmohamed M
Clin Pharmacol Ther; 2018 Apr; 103(4):574-581. PubMed ID: 29392710
[TBL] [Abstract][Full Text] [Related]
16. Influence of metabolic profiles on the safety of drug therapy in routine care in Germany: protocol of the cohort study EMPAR.
Huebner T; Steffens M; Linder R; Fracowiak J; Langner D; Garling M; Falkenberg F; Roethlein C; Gomm W; Haenisch B; Stingl J
BMJ Open; 2020 Apr; 10(4):e032624. PubMed ID: 32345696
[TBL] [Abstract][Full Text] [Related]
17. [Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy].
Rumyantsev NA; Kukes VG; Kazakov RE; Rumyantsev AA; Sychev DA
Ter Arkh; 2017; 89(1):82-87. PubMed ID: 28252633
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics: the path to individualised patient care.
Adelung MR; Fitzsimons VM
Br J Nurs; 2014 Jul 10-23; 23(13):738-9. PubMed ID: 25072336
[No Abstract] [Full Text] [Related]
19. Can pharmacogenetics help rescue drugs withdrawn from the market?
Shah RR
Pharmacogenomics; 2006 Sep; 7(6):889-908. PubMed ID: 16981848
[TBL] [Abstract][Full Text] [Related]
20. Rare disease prevention and treatment: the need for a level playing field.
Hughes DA; Plumpton CO
Pharmacogenomics; 2018 Feb; 19(3):243-247. PubMed ID: 29327657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
